4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one profile

Cross-References

ID Source	ID
PubMed CID	19868
CHEMBL ID	2142704
CHEBI ID	194928
SCHEMBL ID	4902318

Synonyms (44)

Synonym
4-methyl-1,3,4,5-tetrahydro-2h-benzo[b][1,4]diazepin-2-one
BB 0219744
nsc-36330
mls002607962 ,
nsc36330
3967-01-9
AE-473/30685015
OPREA1_799819
nsc 36330
1h-1,5-benzodiazepin-2-one, 2,3,4,5-tetrahydro-4-methyl-
brn 0166063
4-methyl-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-2-one
2-methyl-1,2,3,5-tetrahydro-1,5-benzodiazepin-4-one
4-methyl-1,3,4,5-tetrahydro-2h-1,5-benzodiazepin-2-one
MAYBRIDGE1_000473
AKOS000272070
HMS542N11
F0266-2229
4-methyl-1,3,4,5-tetrahydro-benzo[b][1,4]diazepin-2-one
smr001335214
STK866163
CHEBI:194928
HMS3080B19
EN300-09458
5-24-02-00516 (beilstein handbook reference)
FT-0635078
MS-2384
4-methyl-4,5-dihydro-1h-benzo[b][1,4]diazepin-2(3h)-one
BBPWQLMHOSRDMA-UHFFFAOYSA-N ,
AKOS016039074
SCHEMBL4902318
CHEMBL2142704 ,
W-204277
J-515749
SR-01000394501-1
sr-01000394501
mfcd00024148
bdbm50178217
4-methyl-1,3,4,5-tetrahydro-2h-1,5-benzodiazepin-2one
cpi098
Z56979282
CS-0033862
(rac)-cpi-098
HY-109706

Class	Description
benzodiazepine	A group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vpr	Human immunodeficiency virus 1	Potency	56.2341	1.5849	19.6264	63.0957	AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	220.0000	0.0004	0.4032	9.0500	AID1305377
CREB-binding protein	Homo sapiens (human)	IC50 (µMol)	32.0000	1.3000	6.6892	10.0000	AID1305375
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin organization	Bromodomain-containing protein 4	Homo sapiens (human)
DNA damage response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
regulation of inflammatory response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Bromodomain-containing protein 4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
response to hypoxia	CREB-binding protein	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
chromatin remodeling	CREB-binding protein	Homo sapiens (human)
regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
protein acetylation	CREB-binding protein	Homo sapiens (human)
signal transduction	CREB-binding protein	Homo sapiens (human)
canonical NF-kappaB signal transduction	CREB-binding protein	Homo sapiens (human)
regulation of smoothened signaling pathway	CREB-binding protein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase I	CREB-binding protein	Homo sapiens (human)
N-terminal peptidyl-lysine acetylation	CREB-binding protein	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	CREB-binding protein	Homo sapiens (human)
protein destabilization	CREB-binding protein	Homo sapiens (human)
cellular response to nutrient levels	CREB-binding protein	Homo sapiens (human)
cellular response to UV	CREB-binding protein	Homo sapiens (human)
homeostatic process	CREB-binding protein	Homo sapiens (human)
embryonic digit morphogenesis	CREB-binding protein	Homo sapiens (human)
positive regulation of DNA-templated transcription	CREB-binding protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	CREB-binding protein	Homo sapiens (human)
rhythmic process	CREB-binding protein	Homo sapiens (human)
protein-containing complex assembly	CREB-binding protein	Homo sapiens (human)
regulation of cellular response to heat	CREB-binding protein	Homo sapiens (human)
positive regulation of protein localization to nucleus	CREB-binding protein	Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombination	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Bromodomain-containing protein 4	Homo sapiens (human)
p53 binding	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin binding	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coregulator activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coactivator activity	Bromodomain-containing protein 4	Homo sapiens (human)
protein binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Bromodomain-containing protein 4	Homo sapiens (human)
enzyme binding	Bromodomain-containing protein 4	Homo sapiens (human)
lysine-acetylated histone binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II C-terminal domain binding	Bromodomain-containing protein 4	Homo sapiens (human)
P-TEFb complex binding	Bromodomain-containing protein 4	Homo sapiens (human)
histone reader activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coactivator binding	CREB-binding protein	Homo sapiens (human)
p53 binding	CREB-binding protein	Homo sapiens (human)
chromatin binding	CREB-binding protein	Homo sapiens (human)
damaged DNA binding	CREB-binding protein	Homo sapiens (human)
transcription coactivator activity	CREB-binding protein	Homo sapiens (human)
transcription corepressor activity	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
protein binding	CREB-binding protein	Homo sapiens (human)
zinc ion binding	CREB-binding protein	Homo sapiens (human)
acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
MRF binding	CREB-binding protein	Homo sapiens (human)
histone H3K18 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
histone H3K27 acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
peptide-lysine-N-acetyltransferase activity	CREB-binding protein	Homo sapiens (human)
peptide lactyltransferase activity	CREB-binding protein	Homo sapiens (human)
DNA-binding transcription factor binding	CREB-binding protein	Homo sapiens (human)
chromatin DNA binding	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
condensed nuclear chromosome	Bromodomain-containing protein 4	Homo sapiens (human)
nucleus	Bromodomain-containing protein 4	Homo sapiens (human)
nucleoplasm	Bromodomain-containing protein 4	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
nucleus	CREB-binding protein	Homo sapiens (human)
nucleoplasm	CREB-binding protein	Homo sapiens (human)
cytoplasm	CREB-binding protein	Homo sapiens (human)
cytosol	CREB-binding protein	Homo sapiens (human)
nuclear body	CREB-binding protein	Homo sapiens (human)
chromatin	CREB-binding protein	Homo sapiens (human)
histone acetyltransferase complex	CREB-binding protein	Homo sapiens (human)
transcription regulator complex	CREB-binding protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1305375	Displacement of biotinylated ligand from recombinant His-tagged CBP (unknown origin) incubated for 10 mins by TR-FRET assay	2016	ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
AID1305377	Displacement of biotinylated ligand from recombinant His-tagged BRD4 bromodomain-1 (unknown origin) incubated for 10 mins by TR-FRET assay	2016	ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
AID1305378	Selectivity ratio of IC50 for recombinant His-tagged BRD4 bromodomain-1 (unknown origin) to IC50 for recombinant His-tagged CBP (unknown origin)	2016	ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
AID1305376	Binding affinity to CBP (unknown origin) assessed as increase in melting temperature at 800 uM by SYPRO orange dye based fluorescent thermal shift assay	2016	ACS medicinal chemistry letters, May-12, Volume: 7, Issue:5	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
2-methyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-4-one [no description available]	2.13	1	0	organonitrogen heterocyclic compound; oxacycle

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one

Cross-References

Synonyms (44)

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (32)

Molecular Functions (27)

Ceullar Components (9)

Bioassays (16)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.47

Study Types

4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one

Cross-References

Synonyms (44)

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (32)

Molecular Functions (27)

Ceullar Components (9)

Bioassays (16)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.47

Study Types

Related Drugs (1)

Related Conditions (4)